Efficient in vitro screening for drug combinations: The TEVA model

The value of personalised medicines for healthcare systems in Europe

Oncobox, RNA sequencing and molecular pathway analysis-base system for prescription of target drugs to advanced cancer patients

SPRING 01: Exploring the combination of avelumab, axitinib and palbociclib in patients with advanced metastatic NSCLC

Decision support for precision oncology: Evolving from monotherapy to genomically informed combinations

CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer

Systems immunology in immuno-oncology

Highlights from WIN 2019

Innovation in clinical trials: WINTHER trial

Data sharing and system interoperability: The Osiris French Program

RET inhibition in RET aberrant cancers

Goals of the WIN Consortium

Lifestyle-based prevention strategies to decrease cancer risk

Rewriting the code of life: CRISPR-Cas9 genome editing

Gene expression in primary non-small cell lung cancer as a predictor of brain metastases

A precision medicine approach to therapeutic resistance using KEAP1 somatic mutations

Rapidly changing landscape of precision medicine in Japan

Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies

Optimising patient enrolment and efficacy of precision oncology clinical trials

Integration of DNA and RNA investigations in clinical trials: A laboratory challenge

Direct targeting of STAT3 alone and in combination with immune checkpoint inhibitors to treat solid tumours

Innovative algorithms and IT platform to support clinical trials